Journal ArticleDOI
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update
Neelima Denduluri,Mariana Chavez-MacGregor,Melinda L. Telli,Andrea Eisen,Stephanie L. Graff,Michael J. Hassett,Jamie N. Holloway,Arti Hurria,Tari A. King,Gary H. Lyman,Ann H. Partridge,Mark R. Somerfield,Maureen E. Trudeau,Antonio C. Wolff,Sharon H. Giordano +14 more
Reads0
Chats0
TLDR
Key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjUvant targeted therapy for breast cancer are updated.Abstract:
PurposeTo update key recommendations of the ASCO guideline adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer.MethodsAn Expert Panel conducted targeted systematic literature reviews guided by a signals approach to identify new, potentially practice-changing data that might translate to revised practice recommendations.ResultsThe Expert Panel reviewed phase III trials that evaluated adjuvant capecitabine after completion of standard preoperative anthracycline- and taxane-based combination chemotherapy by patients with early-stage breast cancer HER2-negative breast cancer with residual invasive disease at surgery; the addition of 1 year of adjuvant pertuzumab to combination chemotherapy and trastuzumab for patients with early-stage, HER2-positive breast cancer; and the use of neratinib as extended adjuvant therapy for patients after combination chemotherapy and trastuzumab-based ad...read more
Citations
More filters
Journal ArticleDOI
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Larissa A. Korde,Mark R. Somerfield,Lisa A. Carey,Jennie R. Crews,Neelima Denduluri,E. Shelley Hwang,Seema A. Khan,Sibylle Loibl,Elizabeth A. Morris,Alejandra T. Perez,Meredith M. Regan,Patricia A. Spears,Preeti Sudheendra,W. Fraser Symmans,Rachel L. Yung,Brittany E. Harvey,Dawn L. Hershman +16 more
TL;DR: An Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options found insufficient evidence to support adding immune checkpoint inhibitors to standard chemotherapy.
Journal ArticleDOI
Progress in adjuvant systemic therapy for breast cancer
TL;DR: Attempts to escalate and de-escalate adjuvant systemic treatment for patients with breast cancer are summarized and it is argued that new, creative trial designs focused on patients’ actual needs rather than on maximizing drug market size are needed.
Journal ArticleDOI
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Gideon M. Blumenthal,Paul A. Bunn,Jamie E. Chaft,Caroline E. McCoach,Edith A. Perez,Giorgio V. Scagliotti,David P. Carbone,Hugo J.W.L. Aerts,Dara L. Aisner,Jonas Bergh,Donald A. Berry,Anthony Jarkowski,Nicholas Aj Botwood,Darren Cross,Max Diehn,Nicole L. Drezner,Robert C. Doebele,Collin M. Blakely,Wilfried Eberhardt,Enriqueta Felip,Luca Gianni,Steven P. Keller,Patrick J. Leavey,Shakun Malik,Francesco Pignatti,Tatiana M. Prowell,Tatiana M. Prowell,Mary W. Redman,Naiyer A. Rizvi,Rafael Rosell,Valerie W. Rusch,Dirk De Ruysscher,Lawrence H. Schwartz,Rajeshwari Sridhara,Rolf A. Stahel,Stephen G. Swisher,Janis M. Taube,William D. Travis,Patricia Keegan,Jacinta Wiens,Ignacio I. Wistuba,Murry W. Wynes,Fred R. Hirsch,Mark G. Kris,Mark G. Kris +44 more
TL;DR: Given the success of oncogene‐targeted therapy and immunotherapy for patients with advanced lung cancer, there is a renewed interest in studying these agents in earlier disease settings with the opportunity to have an even greater impact on patient outcomes.
Journal ArticleDOI
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Junjie Li,Junjie Li,Ke-Da Yu,Ke-Da Yu,Da Pang,Changqin Wang,Jun Jiang,Suisheng Yang,Y Liu,Peifen Fu,Yuan Sheng,Guojun Zhang,Yali Cao,Qi He,Shude Cui,Xijing Wang,Guosheng Ren,Xinzheng Li,Shiyou Yu,Pengxi Liu,Xiang Qu,Jinhai Tang,Ouchen Wang,Zhimin Fan,Guoqin Jiang,Jin Zhang,Jiandong Wang,Hongwei Zhang,Shui Wang,Jianguo Zhang,Feng Jin,Nanyan Rao,Binlin Ma,Ping-qing He,Binghe Xu,Zhigang Zhuang,Jianfeng Wang,Qiang Sun,Xiaofeng Guo,Miao Mo,Zhimin Shao,Zhimin Shao +41 more
TL;DR: Capecitabine when added to 3 cycles of docetaxel followed by3 cycles of a 3-drug anthracycline combination containing cape citabine instead of fluorouracil significantly improved DFS in TNBC without new safety concerns.
Journal ArticleDOI
The Exciting New Field of HER2-Low Breast Cancer Treatment.
TL;DR: The authors in this paper reviewed the body of evidence of HER2-low BC that led to the study of first-generation anti-HER2 agents, like trastuzumab, and how they have failed to achieve any clinical applicability in this setting.
References
More filters
Journal ArticleDOI
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
Andreas Schneeweiss,Stephen Chia,Tamas Hickish,Vernon Harvey,Alexandru Eniu,Roberto Hegg,C. Tausch,J.H. Seo,Y.-F. Tsai,Jayantha Ratnayake,V. McNally,Graham Ross,Javier Cortes +12 more
TL;DR: The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD, and the tolerability of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer was assessed.
Journal ArticleDOI
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Heikki Joensuu,Pirkko-Liisa Kellokumpu-Lehtinen,Riikka Huovinen,Arja Jukkola-Vuorinen,Minna Tanner,R. Kokko,Johan Ahlgren,Päivi Auvinen,Outi Lahdenperä,Sanna Kosonen,Kenneth Villman,Paul Nyandoto,Greger Nilsson,Paula Poikonen-Saksela,Vesa Kataja,Jouni Junnila,Petri Bono,Henrik Lindman +17 more
TL;DR: The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer (TNBC).
Journal ArticleDOI
Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials
Akina Natori,Josee-Lyne Ethier,Josee-Lyne Ethier,Eitan Amir,Eitan Amir,David W. Cescon,David W. Cescon +6 more
TL;DR: Adding capecitabine to standard chemotherapy appears to improve DFS and OS in TNBC, but increases adverse events in keeping with its known toxicity profile.
Related Papers (5)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz,Chiun Sheng Huang,Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Michael Untch,Norman Wolmark,P Rastogi,Andreas Schneeweiss,Andrés Redondo,Hans Holger Fischer,William Jacot,Alison Conlin,Claudia Arce-Salinas,Irene Wapnir,Christian Jackisch,Michael P. DiGiovanna,Peter A. Fasching,John Crown,Pia Wülfing,Zhimin Shao,Elena Rota Caremoli,Haiyan Wu,Lisa H. Lam,David Tesarowski,Melanie C. Smitt,Hannah Douthwaite,Stina M. Singel,Charles E. Geyer +28 more
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more